Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 901–1,000 of 1,003
Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents
Fusco, S. A. D., Lucà, F., Benvenuto, M., Iorio, A., Fiscella, D., D’Ascenzo, F., Madeo, A., Colivicchi, F., Lenarda, A. D., & Gulizia, M. M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.05.060 · Cited by 15
The prevention of venous thromboembolism recurrence in the elderly: a still open issue
Palareti, G., & Poli, D. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1526667 · Cited by 14
Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
Kim, S., Yhim, H., & Bang, S. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e52 · Cited by 17
Overview of venous pathology related to repetitive vascular trauma in athletes
Menon, D., Onida, S., & Davies, A. H. (2019) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2019.03.012 · Cited by 16
Gustafsson, N., Poulsen, P. B., Stallknecht, S. E., Dybro, L., & Johnsen, S. P. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz035 · Cited by 16
Hlavacek, P., Guo, J. D., Rosenblatt, L. C., Keshishian, A. V., Russ, C., Mardekian, J., Ferri, M., Poretta, T., Yüce, H., & McBane, R. D. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1653067 · Cited by 16
Critical Analysis of Apixaban Dose Adjustment Criteria
Vu, A., Qu, T. T., Ryu, R. J., Nandkeolyar, S., Jacobson, A. K., & Hong, L. T. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211021158 · Cited by 14
“To evaluate apixaban use for the treatment of acute VTE, 2,691 patients were randomized to receive 10 mg of apixaban twice daily for the first 7 days, then subsequently 5 mg twice daily or enoxaparin at a dose of 1 mg/kg subcutaneously twice daily for 5 days bridging to warfarin for 6 months.(19) Fixeddose apixaban wa…”
MethodNon-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
Blann, A. D., & Lip, G. Y. H. (2016) · Heart · doi:10.1136/heartjnl-2014-307019 · Cited by 15
Schultz, N. H., Tran, H. T. T., Bjørnsen, S., Henriksson, C. E., Sandset, P. M., & Holme, P. A. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12015 · Cited by 14
Pritchard, E. R., Murillo, J. R., Putney, D. R., & Hobaugh, E. C. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217726158 · Cited by 14
Ahuja, T., Raco, V., Papadopoulos, J., & Green, D. (2021) · PubMed · doi:10.1097/pts.0000000000000535 · Cited by 13
Schenker, C., Stalder, O., Méan, M., Tritschler, T., Righini, M., Rodondi, N., & Aujesky, D. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1760365 · Cited by 14
Acute Pulmonary Embolism: Evidence, Innovation, and Horizons
Henkin, S., Ujueta, F., Sato, A., & Piazza, G. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02128-0 · Cited by 14
“Several studies have shown DOACs to have a similar treat-ment efficacy as warfarin or heparin in the management of patients with low-risk PE [53–55].”
Ikeda, N., Yamashita, Y., Morimoto, T., Chatani, R., Kaneda, K., Nishimoto, Y., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035997 · Cited by 15
Durie, R., Kohute, M., Fernandez, C. A. A., & Knight, M. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12339 · Cited by 13
Rankin, J., Nagar, M., Crosby, J., Toomari, N., Pietras, R. J., & Ben-Zur, U. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-1135-9 · Cited by 13
“Similarly, the AMPLIFY and Hokusai-VTE trials showed non-inferiority of apixaban and edoxaban, respectively, when compared with warfarin in the treatment of VTE, with a significant reduction in bleeding events [9, 10].”
MethodVoigtlaender, M., & Länger, F. P. (2017) · Hämostaseologie · doi:10.5482/hamo-16-09-0036 · Cited by 14
Farge, D., & Frère, C. (2019) · F1000Research · doi:10.12688/f1000research.18673.1 · Cited by 15
Lin, K. J., Schneeweiß, S., Pawar, A. M., Singer, D. E., Liu, J., & Gagne, J. J. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1508-8187 · Cited by 14
Towers, W. F., Nguyen, S. N., Ruegger, M. C., Salazar, E., & Donahue, K. R. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211046087 · Cited by 13
Haas, S. K., Farjat, A. E., Pieper, K. S., Ageno, W., Angchaisuksiri, P., Bounameaux, H., Goldhaber, S. Z., Goto, S., Mantovani, L. G., Prandoni, P., et al. (2022) · TH Open · doi:10.1055/s-0042-1757744 · Cited by 13
Self-citationEbertz, D. P., Bose, S., Smith, J. S., Sarode, A. L., Ambani, R. N., Cho, J. S., Kumins, N. H., Kashyap, V. S., & Colvard, B. (2022) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2022.12.012 · Cited by 13
Acute pulmonary embolism: risk assessment, risk stratification and treatment options
Piovella, F., & Iosub, D. I. (2015) · The Clinical Respiratory Journal · doi:10.1111/crj.12264 · Cited by 16
“The AMPLIFY study compared apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily) as a single-drug therapy with enoxaparin/VKA therapy for 6 months in patients with acute VTE (Table 3) (41).”
BackgroundMethodPulmonary embolism: current and new treatment options
Walter, R. J., Moores, L. K., & Jiménez, D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.936931 · Cited by 13
MORISHIMA, Y., Kamisato, C., & Honda, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.020 · Cited by 14
New oral anticoagulants – a review
Ghanima, W., Atar, D., & Sandset, P. M. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.1111 · Cited by 18
“Apixaban treatment of patients with acute deep vein thrombosis and/or pulmonary embolism was non-inferior to conventional treatment (28).”
BackgroundCombining oral anticoagulation and antiplatelet therapies: appropriate patient selection
Vandiver, J. W., & Beavers, K. D. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1635-0 · Cited by 14
Update on diagnosis and anticoagulant therapy for venous thromboembolism
Stevens, H., & Tran, H. A. (2018) · Internal Medicine Journal · doi:10.1111/imj.14063 · Cited by 13
Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates.
Wang, K.-L., Kao, Y., Chang, W., Chang, H., Huang, W. C., Hsu, P., Hsu, C., Huang, C.-L., Hsieh, L., Wang, C.-Y., et al. (2020) · PubMed Central · doi:10.6515/acs.202011_36(6).20200917a · Cited by 15
Andrews, L. J., Benken, S. T., Tan, X., & Wenzler, E. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02248-7 · Cited by 13
Development and validation of LC-MS/MS method for determination of plasma apixaban
Džudović, J., Crevar, M., Antunović, M., Repić, A., Obradovic, S. D., Djordjevic, S., Savić, J. S., & Džudović, B. (2021) · Acta Chromatographica · doi:10.1556/1326.2021.00948 · Cited by 13
Zwicker, J. I., & Bauer, K. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5184 · Cited by 15
Acute Perioperative Pulmonary Embolism—Management Strategies and Outcomes
Cormican, D. S., Morkos, M. S., Winter, D., Rodrigue, M. F., Wendel, J., & Ramakrishna, H. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.11.018 · Cited by 13
Goldhaber, S. Z., Ageno, W., Casella, I. B., Chee, K. H., Schellong, S., Singer, D. E., Desch, M., Reilly, P. A., Donado, E., Tang, W., et al. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.036 · Cited by 13
Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle?
Verhamme, P. B., & Bounameaux, H. (2013) · Circulation · doi:10.1161/circulationaha.113.007478 · Cited by 14
“The results of all 4 DOACs for the acute treatment of VTE are summarized in Table 1.(4-8)”
BackgroundOff-label use of novel anticoagulants for treatment of cerebral venous thrombosis: A Canadian survey
Field, T. S., Camden, M., Alshimemeri, S. A., Lui, G., & Lee, A. Y. Y. (2016) · International Journal of Stroke · doi:10.1177/1747493015616643 · Cited by 13
“Duration of practice, y Resident/fellow 0 (0) 1 (3) 0.”
BackgroundInfluentialQuon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Safety and efficacy of oral anticoagulants in extreme weights
Chin-Hon, J., Davenport, L., Huang, J. C., Akerman, M. B., & Hindenburg, A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.09.001 · Cited by 12
Dobry, P., Edwin, S. B., Haymart, B., Barnes, G. D., Kaatz, S., Ali, M. A., & Giuliano, C. A. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.08.009 · Cited by 12
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 18
Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach
Cohen, A. T., & Black, S. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1028 · Cited by 15
Self-citationUsing direct oral anticoagulants (DOACs) in cancer and other high-risk populations
van Es, N., & Buller, H. R. (2015) · Hematology · doi:10.1182/asheducation-2015.1.125 · Cited by 14
Self-citationAn Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 14
Reversal strategies in patients treated with direct oral anticoagulants
Gressenberger, P. (2019) · VASA · doi:10.1024/0301-1526/a000777 · Cited by 14
Davila, J. G., Cheng, D., Raffini, L. J., Thornburg, C. D., & Corrales‐Medina, F. F. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.10.029 · Cited by 12
Guo, J. D., Hlavacek, P., Rosenblatt, L. C., Keshishian, A. V., Russ, C., Mardekian, J., Ferri, M., Poretta, T., Yüce, H., & McBane, R. D. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.039 · Cited by 12
Tan, S. L., Yong, Z. Y., Liew, J. E. S., Zainal, H., & Siddiqui, S. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00377-w · Cited by 12
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_19 · Cited by 14
Tsai, S. H. L., Hu, C.-W., Shao, S., Tischler, E. H., Obisesan, O. H., Vervoort, D., Chen, W., Hu, J., & Kuo, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.896952 · Cited by 13
Wu, S., Lv, M., Chen, J., Jiang, S., Chen, M., Fang, Z., Zeng, Z., Qian, J., Xu, W., Guan, C., et al. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07433-4 · Cited by 15
Alshaya, O. A., Korayem, G. B., Yami, M. S. A., Qudayr, A. H., Althewaibi, S., Fetyani, L., Alshehri, S. D., Alnashmi, F., Albasseet, M., Alshehri, L. A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010199 · Cited by 12
Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis
Camerlo, S., Ligato, J., Rosati, G., Carrà, G., Russo, I., Gobbi, M. D., & Morotti, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032262 · Cited by 16
Toyoda, Ḱ., Arakawa, S., Ezura, M., Kobayashi, R., Tanaka, Y., Hasegawa, S., Yamashiro, S., Komatsu, Y., Terasawa, Y., Masuno, T., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64223 · Cited by 12
Zhang, S., Zhai, Z., Yang, Y., Zhu, J., Kuang, T., Xie, W., Yang, S., Liu, F., Gong, J., Shen, Y. H., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.142 · Cited by 13
“Additionally, the recurrent incidence was higher in our study compared with recent randomized controlled trials (RCTs) investigating novel oral anticoagulants [26,27].”
ResultTransitioning to and from the novel oral anticoagulants: a management strategy for clinicians
Abo‐Salem, E., & Becker, R. C. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1060-y · Cited by 12
Hull, R. D., & Gersh, M. H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.975786 · Cited by 13
Management of Apixaban-Associated Subdural Hematoma
Rinehart, D. R., Lockhart, N. R., Hamilton, L. A., Langdon, J. R., & Rowe, A. S. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000000909 · Cited by 12
Update on the Treatment of Venous Thromboembolism
Schulman, S. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1592305 · Cited by 14
Safety of warfarin in “high-risk” populations: A meta-analysis of randomized and controlled trials
Minno, M. N. D. D., Ambrosino, P., & Dentali, F. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.12.005 · Cited by 14
Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know.
Amin, A. (2016) · PubMed · Cited by 14
Chopard, R., Andarelli, J. N., Humbert, S., Falvo, N., Morel-Aleton, M., Bonnet, B., Napporn, G., Kalbacher, E., Obert, L., Degano, B., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.12.013 · Cited by 12
Sy, J., Hsiung, J.-T., Edgett, D., Kalantar‐Zadeh, K., Streja, E., & Lau, W. L. (2021) · American Journal of Nephrology · doi:10.1159/000514753 · Cited by 14
Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients
Jin, M. C., Sussman, E. S., Feng, A. Y., Han, S. S., Skirboll, S. L., Berube, C., & Ratliff, J. K. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.06.015 · Cited by 12
Cohen, A. T., Sah, J., Dhamane, A. D., Lee, T. T. H., Rosenblatt, L. C., Hlavacek, P., Emir, B., Keshishian, A. V., Yüce, H., & Luo, X. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01918-0 · Cited by 12
“Minorities and patients with lower SES have been underrepresented in clinical trials [13], and evidence on the effectiveness and safety of anticoagulants in patients with VTE with different 5520 Adv Ther (2021) 38:5519–5533”
BackgroundInfluentialSelf-citationPhillippe, H. M., Wright, B. M., Bowerman, K. E., & Andrus, M. R. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516672693 · Cited by 12
“Rivaroxaban and apixaban showed a lower incidence of major bleeding when compared to warfarin therapy, and all 4 agents had a lower incidence of intracranial hemorrhage when compared to warfarin.(19-24) Dabigatran had a higher incidence of GI bleed when compared to warfarin therapy.”
BackgroundAcute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series
Nassif, T., Banchs, J. A., Yusuf, S. W., & Mouhayar, E. (2017) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytx018 · Cited by 15
“These drugs have been shown to have similar efficacy and bleeding risks to those of other standard anticoagulants.(1,2) However, The National Comprehensive Cancer Network guidelines recommend against using DOACs in cancer patients(3) on the basis of limited data regarding their safety in these patients.”
BackgroundA Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge
Josyln, J. A., Khattak, F. H., & Geraci, S. A. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3394w · Cited by 12
“In comparison to warfarin, these drugs appeared therapeutically non-inferior, and in some cases superior (for non-valvular atrial fibrillation-related stroke prophylaxis, deep vein thrombosis (DVT) prophylaxis, and DVT/pulmonary embolism treatment) and as safe or safer regarding major bleeding (intracranial, gastroint…”
ResultGu, Z., Yan, Y., Yang, S.-Y., Shen, L., Kong, L.-C., Zhang, C., Wei, A., Li, Z., Wang, X., & Lin, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.12.152 · Cited by 12
Sorigué, M., Cañamero, E., Sigüenza, P., Nomdedéu, M., & López-Núñez, J. J. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1713321 · Cited by 13
What gastroenterologists should know about direct oral anticoagulants
Radaelli, F., Fuccio, L., Paggi, S., Bono, C. D., Dumonceau, J., & Dentali, F. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.04.032 · Cited by 13
Ikeda, N., Amemiya, K., Sato, S., Iijima, R., Hara, H., & Nakamura, M. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01799-x · Cited by 12
Zou, H., Li, Y., & Xu, G. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1637-y · Cited by 12
“Apixaban, as a DOAC, provides an effective and safe regimen for the initial and long-term treatment of DVT and PE compared to conventional therapy (subcutaneous enoxaparin, followed by warfarin) and reduces the risk of recurrent DVT and PE compared to placebo following initial therapy [40, 41].”
BackgroundEdoxaban versus Warfarin for Venous Thromboembolism
Buller, H. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1313883 · Cited by 12
Self-citationJugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1027 · Cited by 11
“68 % (189/2462), log-transformed with respect to time (7); l –18-months incidence of major or clinically relevant non-major bleeding event: 10.”
BackgroundDrug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Kaneda, K., Yamashita, Y., Morimoto, T., Chatani, R., Nishimoto, Y., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034412 · Cited by 11
Schaefer, J. K., Errickson, J., Kong, X., Ali, M. A., Chipalkatti, N., Haymart, B., Kaatz, S., Krol, G. D., Sood, S. L., Froehlich, J. B., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101714 · Cited by 11
Galanis, T., Keiffer, G., & Merli, G. J. (2014) · Current Therapeutic Research · doi:10.1016/j.curtheres.2014.06.002 · Cited by 12
“The Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy (AMPLIFY) trial was a randomized, double-bind study comparing apixaban (10 mg twice daily for the first 7 days followed by 5 mg twice daily) to standard therapy (low–molecular-weight heparin followed by warfari…”
BackgroundNafee, T., Aslam, A., Chi, G., Pahlavani, S., Nimri, D., Kuchkuntla, A. R., Talib, U., Michalak, N., Daaboul, Y., Korjian, S., et al. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1305889 · Cited by 11
Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease
Febres, L. M. S., & Manteca, J. C. (2017) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2017.01.010 · Cited by 11
“302 In AMPLIFY, compared with standard treatment, apixaban reduced the 303 risk of major bleeding by 69% after 6 months of treatment, although the patients 304 were lower-risk (the study population did not include patients with cancer, 305 patients expected to undergo long-term anticoagulation therapy with 306 enoxapa…”
BackgroundDirect Oral Anticoagulants in Cancer Patients
Suryanarayan, D., Lee, A. Y. Y., & Wu, C. S. T. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1693479 · Cited by 11
Contemporary clinical management of acute pulmonary embolism: the COPE study
Becattini, C., Agnelli, G., Maggioni, A. P., Dentali, F., Fabbri, A., Enea, I., Pomero, F., Ruggieri, M. P., Lenarda, A. D., & Gulizia, M. M. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02855-0 · Cited by 13
“These agents have been developed for clinical use according to 2 different regimens for the treatment of venous thromboembolism (6,16-21).”
MethodSelf-citationVoigtlaender, M., Edler, C., Gerling, M., Schädler, J., Ondruschka, B., Schröder, A. S., Sperhake, J. P., Ehrhardt, S., Wang, L., Haddad, M., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.08.021 · Cited by 12
“In contrast, recent clinical trials on the treatment of acute VTE report PT-to-DVT ratios of 1:2 [20].”
Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known
Ingason, A. B., Hreinsson, J. P., & Bjornsson, E. S. (2022) · Drug Safety · doi:10.1007/s40264-022-01243-7 · Cited by 13
Faber, L. L., Geary, R. L., Chang, K., Goldman, M. P., Freischlag, J. A., & Velazquez, G. A. (2022) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2022.09.012 · Cited by 11
Merali, S. J., Byon, W., Patel, Y. T., Elsrougy, A., Marchisin, D., Perera, V., Chen, W., He, B., & Murthy, B. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12935 · Cited by 11
Beyer‐Westendorf, J., Cohen, A. T., & Monréal, M. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv034 · Cited by 13
Self-citationDabigatran in clinical practice: Contemporary overview of the evidence
Ageno, W., Eikelboom, J. W., & Lip, G. Y. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.078 · Cited by 13
“This differs from the approach used in trials of apixaban (AMPLIFY trial) and rivaroxaban (EINSTEIN-DVT study), which can be started from the disease onset.[46, 47] There is no direct comparison”
Imberti, D., Barillari, G., & for the eXperience VTE Italian Group (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617720067 · Cited by 11
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients
Kraaijpoel, N., van Es, N., Bleker, S. M., Brekelmans, M. P. A., Eerenberg, E. S., Middeldorp, S., Cohen, A. T., Raskob, G. E., & Buller, H. R. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-04-0274 · Cited by 11
“Clinical presentation classification Cancer (n=50) n (%) No cancer (n= 240) n (%) Category 1 8 (16) 42 (17) Category 2 23 (46) 93 (39) Category 3 18 (36) 100 (42) Category 4 1 (2) 5 (2)”
Self-citationTreatment of Cancer-Associated Thrombosis: Beyond HOKUSAI
Mahé, I., Elalamy, I., Gerotziafas, G., & Girard, P. (2019) · TH Open · doi:10.1055/s-0039-1696659 · Cited by 11
Nourse, J. P., & Danckwardt, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107676 · Cited by 11
García-Escobar, I., Brozos-Vázquez, E., Abad, D. G., Martínez-Marín, V., Pachón, V., & Martín, A. J. M. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02506-4 · Cited by 13
“These include the RE-COVER [23] and RE-COVER II [24] studies with dabigatran, the EINSTEIN-DVT study for DVT [54] and EINSTEIN-PE for PE [55] with rivaroxaban, and the AMPLIFY study [38] with apixaban (Table 1).”
BackgroundMethodDirect Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure
White, E. M., & Coons, J. C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01456-9 · Cited by 11
Effects of Short-Term Air Pollution Exposure on Venous Thromboembolism: A Case-Crossover Study
Johnson, S. A., Mendoza, D. L., Zhang, Y., & Pirozzi, C. S. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202010-1337oc · Cited by 11
Sedhom, R., Megaly, M. S., Gupta, E., & Amanullah, A. M. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02501-8 · Cited by 12
Singh, B. B., Pai, P., Kumar, H., George, S., Mahapatra, S., Garg, V., Gupta, G. N., Makineni, K., Ganeshwala, G., Narkhede, P., et al. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00254-w · Cited by 11
“The efficacy of twice daily dose of apixaban was observed in AMPLIFY and AMPLIFY-EXT study [23, 24].”
BackgroundLiu, Z., Zhang, H., Ma, L., Mu, G., Xie, Q., Zhou, S., Wang, Z., Wang, Z., Hu, K., Xiang, Q., et al. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02550-8 · Cited by 11
Chen, J., Nguyen, S. N., Ruegger, M. C., Samuel, L., Salazar, E., & Dunne, I. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02650-4 · Cited by 11
“6% of patients receiving apixaban for VTE in the AMPLIFY trial [20].”
BackgroundResultObradovic, S. D., Subotić, B., Džudović, B., Matijašević, J., Džudović, J., Šalinger-Martinović, S., Miloradović, V., Kovačević-Preradović, T., Marinković, J., & Nešković, A. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.05.002 · Cited by 11
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.